Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26362145 | 1.00 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL21844963 | 1.00 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL16878094 | 1.00 | KCNH2 (0.37) | KCNH2 | |
| SCHEMBL16877770 | 0.97 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL16878311 | 0.97 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL16878665 | 0.97 | — | — | |
| SCHEMBL16877697 | 0.97 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL3658994 | 0.97 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL3505574 | 0.93 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL12096483 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044486-A1 | JAK2 INHIBITOR COMPOUNDS | AJAX THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2012058591-A1 | BIOMATERIAL COMPOSITIONS | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2012-05-03 | — | — | WO | claimed |
| EP-1746988-A1 | SPIRODERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Darley Pharmaceuticals Ltd. (IL) | 2007-01-31 | — | — | EP | claimed |
| WO-2005107739-A1 | SPIRODERIVATIVES FOR THE TREATMENT OF HYPERTENSION | DARLEY PHARMACEUTICALS LTD. (IL) | 2005-11-17 | — | — | WO | claimed |
| EP-0102193-B1 | STABILIZERS FOR SYNTHETIC RESINS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1986-10-29 | — | — | EP | claimed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | GENESIS THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | GENESIS MOLECULAR AI INC (US) | 2026-05-14 | — | — | US | disclosed |
| CN-122029160-A | Method for preparing PI3K inhibitor | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4727939-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727938-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| US-5389634-A | Treating arterial hypertension, relaxing uterus, prevention of post-angioplastic restenosis | ROUSSEL-UCLAF (FR) | 1995-02-14 | — | — | US | disclosed |
| US-5338756-A | Angiotensin II receptor antagonists | ROUSSEL UCLAF (FR) | 1994-08-16 | — | — | US | disclosed |
| US-5190974-A | Analgesics | ROUSSEL UCLAF (FR) | 1993-03-02 | — | — | US | disclosed |
| US-4761501-A | INTERMEDIATES FOR ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0112669-B1 | PHENETHYLAMINE DERIVATIVES AND INTERMEDIATES THEREFOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4611078-A | ANTIDEPRESSANT INTERMEDIATES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4535186-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS; VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0112669-A2 | Phenethylamine derivatives and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | PIK3R4, PIK3R1, PIK3R5 | KCNH2 1799/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | KCNH2 2114/4885 |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | PIK3R1, PIK3R5, PIK3R2 | KCNH2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.